Publication at Faculty of Medicine in Pilsen |
2016
Abstract
Author mentioned new WHO classification of malignant lung tumours. Recently, emphasis is given on immunohistochemistry and genetics.
Author noticed also new methods of therapeutic response evaluation inrelation with targeted therapy and immunotherapy. Recently besides of RECIST new evaluation systems PERCIST and imuno RECIST are used.
Author mentioned also possible serious adverse events of lung cancer immunotherapy.